SCHEMBL6330924

SCHEMBL6330924

CCCCCc1ccc(S(=O)(=O)N(C)[C@H](C)CS)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.45
CNR2 P34972 1/20 0.43
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
HPGD P15428 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
MLNR O43193 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
S1PR2 O95136 1/20 0.39
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330921 1.00 CA2 (0.51) CA2SMN1; SMN2CNR2LMNAHTT
SCHEMBL6323652 0.86 CA2 (0.51) CA2SMN1; SMN2CNR2LMNAHTT
SCHEMBL6323645 0.86 CA2 (0.51) CA2SMN1; SMN2CNR2LMNAHTT
SCHEMBL6328874 0.82 CA2 (0.47) CA2SMN1; SMN2CNR2LMNAHTT
SCHEMBL6323349 0.81 MMP3 (0.51) CA2LMNAHTTCA12CA1
SCHEMBL6323355 0.81 MMP3 (0.51) CA2LMNAHTTCA12CA1
SCHEMBL6328876 0.79 CA2 (0.44) CA2SMN1; SMN2CNR2THRATHRB
SCHEMBL6330926 0.78 ADAM17 (0.53) CA2SMN1; SMN2CNR2LMNAHTT
SCHEMBL7856535 0.77 CA2 (0.62) CA2SMN1; SMN2CNR2LMNAHTT
SCHEMBL12040860 0.77 CA2 (0.62) CA2SMN1; SMN2CNR2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed
EP-0939629-A4 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO CO (US) 2002-07-17 EP disclosed
EP-0939629-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1999-09-08 EP disclosed
WO-1998003166-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CA2 492/4885SMN1; SMN2 2514/4885CNR2 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.